Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolytics Biotech has received Canadian patent for the claims which describe the use of one or more recombinant reoviruses to treat Ras-mediated proliferative disorders.
Subscribe to our email newsletter
Mary Dillahunty, vice president of intellectual property at Oncolytics, said: “This patent provides the company with additional patent protection for the use of reovirus compositions for cancers and other cellular proliferative disorders in Canada.”